The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2015

Filed:

Dec. 18, 2013
Applicant:

Regents of the University of Minnesota, Minneapolis, MN (US);

Inventors:

Karen Hsiao Ashe, North Oaks, MN (US);

Xiaohui Zhao, Woodbury, MN (US);

Michael Anthony Walters, Minneapolis, MN (US);

Derek John Hook, San Diego, CA (US);

Morgan Clotaire Paul Le Naour, Minneapolis, MN (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); C12Q 1/37 (2006.01); A61K 38/00 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); C07K 14/4711 (2013.01); C12Q 1/37 (2013.01); A61K 38/00 (2013.01); C07K 2317/34 (2013.01); G01N 2500/04 (2013.01); G01N 2800/2821 (2013.01);
Abstract

Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2.


Find Patent Forward Citations

Loading…